Pregnancy-associated plasma protein A during hemodialysis with polyamide and diacetate cellulosic membranes

International Journal of Artificial Organs

Volumn 27, Issue 11, 2004, Pages 943-948

  Kalousová, Marta ^a   Lachmanova J ^a   Mokrejsova M ^a   Mikova B ^b   Fialova L ^a   Malbohan, I M ^a   Tesar V ^a   Zima, T ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Railway Hospital   (Czech Republic)

Author keywords

Biocompatibility; Hemodialysis; Inflammation; Oxidative stress; PAPP A; Pregnancy associated plasma protein A

Indexed keywords

BIOCOMPATIBILITY; HEMODIALYZERS; MEMBRANES; OBSTETRICS; OXIDATIVE STRESS; PATHOLOGY; PATIENT MONITORING; PATIENT TREATMENT; PROTEINS;

CORONARY SYNDROMES; HAEMODIALYSIS; HEMODIALYSIS PATIENT; PLASMA PROTEIN; PREGNANCY-ASSOCIATED PLASMA PROTEIN A; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROGNOSTIC FACTORS; PROTEIN A;

DIALYSIS;

ACETOACETIC ACID; ANTIHYPERTENSIVE AGENT; ERYTHROPOIETIN; INTERLEUKIN 6; POLYAMIDE; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BIOCOMPATIBILITY; CLINICAL ARTICLE; FEMALE; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE; MALE; OXIDATIVE STRESS; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN SECRETION;

EID: 12544253718     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880402701106     Document Type: Article

References (25)

1. Vanholder R, Argiles A, Baurmeister U, et al. Uremic toxicity: Present state of the art. Int J Artif Organs 2001; 24: 695-725.
2. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-80.
3. Horl WH. Hemodialysis membranes: interleukines, biocompatibility, and middle molecules. J Am Soc Nephrol 2002; 13 (suppl 1): S62-71.
4. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001; 345: 1022-9.
5. Kalousova M, Sulkova S, Fialova L, et al. Glycoxidation and inflammation in chronic hemodialysis patients. Nephrol Dial Transplant 2003; 18: 2577-81.
6. Lawrence JB, Oxvig C, Overgaard MT, et al. The insulin-like growth factor-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy associated plasma protein-A. Proc Natl Acad Sci 1999; 96: 3149-53.
7. Laursen LS, Overgaard MT, Soe R, et al. Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: Implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett 2001; 504: 36-40.
8. Monget P, Mazerbourg S, Delpuech T, et al. Pregnancy-associated plasma protein-A is involved in insulin-like growth factor binding protein-2 (IGFBP-2) proteolytic degradation in bovine and porcine preovulatory follicles: Identification of cleavage site and characterization of IBFBP-2 degradation. Biol Reprod 2003; 68: 77-86.
9. Fialova L, Kalousova M, Soukupova J, et al. Relationship of pregnancy-associated plasma protein A (PAPP-A) to renal function and dialysis modalities. Kidney Blood Press Res 2004; 27: 88-95.
10. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in ureamia. Kidney Int 1996; 49: 1304-13.
11. Henle T, Deppisch R, Beck W, Hergesell O, Hansch G, Ritz E. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogenity of AGE compounds. Nephrol Dial Transplant 1999; 14: 1968-75.
12. Munch G, Kies R, Wessel A, et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997; 35: 669-77.
13. Lund J, Qiu-Ping O, Ilva T, et al. Circulating pregnancy-associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003; 108: 1924-6.
14. Beaudeux JL, Burc L, Imbert-Bismut F, et al. Serum plasma pregnancy-associated protein A: A potential marker of echogenic atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler Thromb Vasc Biol 2003; 23: 7-10.
15. Jones JI, Prevette T, Gockerman A, Clemmons DR. Ligand occupancy of the αVβ3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl Acad Sci USA 1996; 96: 2482-7.
16. Renier G, Clement I, Desfaits AC, Lambert A. Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-α production. Endocrinology 1996; 137: 4611-8.
17. Bayes-Genis A, Schwartz RS, Lewis DA, et al. Insulin-like growth factor binding protein-4 protease produced by smooth muscle cells increases in the coronary artery after angioplasty. Arterioscler Thromb Vasc Biol 2001; 21: 335-41.
18. Kalousova M, Horejsi M, Fialova L, et al. Increased levels of pregnancy-associated plasma protein A (PAPP-A) are associated with mortality of haemodialysis patients: preliminary results. Blood Purif 2004; 22: 298-300.
19. Oxving C, Sand O, Kristensen T, et al. Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. J Biol Chem 1993; 268: 12243-6.
20. Qin QP, Christiansen M, Petterson K. Point-of-care time-resolved immunofluorimetric assay for human pregnancy associated plasma protein A (PAPP-A) for use in first-trimester screening for Down syndrome. Clin Chem 2002; 48: 473-83.
21. Qin QP, Laitinen P, Majamaa-Voltti K, Ericksson S, Kumpula EK, Pettersson K. Release petterns of pregnancy-associated plasma protein A (PAPP-A) in patients with acute coronary syndromes. Scand Cardiovasc J 2002; 36: 358-61.
22. Kaplow LS, Goffinet JA. Profound neutropenia during the early phase of hemodialysis. JAMA 1968; 203: 1135-7.
23. Kalousova M, Zima T, Tesar V, Lachmanova J. Advanced glycation end products and advanced oxidation protein products in hemodialysis patients. Blood Purif 2002; 20: 531-6.
24. Rosenkranz AR, Templ E, Traindl O, Heinzl H, Zlabinger GJ. Reactive oxygen product formation by human neutrophils as an early marker for biocompatibility of dialysis membranes. Clin Exp Immunol 1994; 98: 300-5.
25. Zima T, Haragsim L, Štípek S, Bártová V, Němeček K. Lipid peroxidation on dialysis membrane. Biochem Mol Biol Int 1993; 29: 531-7.